BenevolentAI installs new Head of Cheminformatics
BenevolentAI, a company that uses an artificial intelligence platform to improve drug discovery, has announced the appointment of Nathan Brown as its Head of Cheminformatics. The move comes after the previous holder of the position, Mark Davies, was promoted to VP of Biomedical Informatics.
Brown arrives at the company after having had a 10-year stay at the Institute of Cancer Research. At the ICR, Brown founded and led an In Silico Medicinal Chemistry Group geared towards researching novel cancer treatments. Prior to his work at the ICR, he had been awarded a Marie Curie Fellowship, after completing his doctoral studies, to work with Avantium in Amsterdam.
Brown’s area of expertise is in software design and developer in medicinal chemistry and cancer biology. He has had three books published in the area, with the last being In Silico Medicinal Chemistry written for the Royal Society of Chemistry.
Jackie Hunter, CEO of BenevolentBIo, the bioscience subsidiary of BenevolentAI, commented on the appointment: “Nathan Brown is a recognised leader in the field of cheminformatics, molecular informatics and computational chemistry. He has done exceptional work in the development of innovative anti-cancer therapies in an academic setting and his work is respected and well published. We are delighted to have Nathan on board.”
BenevolentAI noted that the appointment was part of a larger recruitment drive, as the company continues to grow. Pharmafocus caught up with founder of the company, Ken Mulvany, recently as part of a wider feature on AI’s place within drug discovery.